RADUE , Ernst-Wilhelm

Background Multiple sclerosis (MS) affects all areas of the brain resulting in both focal and diffuse damage. In Phase 3 clinical trials, fingolimod showed significant reductions in both focal lesions and rate of brain volume loss (BVL) in patients with relapsing-remitting MS. Objective To investigate if the effects of fingolimod 0.5 mg on BVL...